BioPharm International-10-01-2010

Biopharmaceutical Approvals in the US and EU: A Review

Venture capital is still scarce for early biotechs and their providers.

Can vendor-user partnerships overcome the typical wait-and-see attitude toward new technologies?

Biotech approvals were up last year. Is it a sign of a new trend?

How should the industry educate the public about product quality?

A new strategy to streamline vaccine development and oversight.

Good leaders look beyond industry woes to focus on patients

Biotech's mid-sized elites position themselves for growth.

Industry and regulators disagree over noncritical parameters.